Erhalten Sie eine woechentliche Zusammenfassung der neuesten psychedelischen Forschung, neuer Studien und Plattform-Updates direkt in Ihren Posteingang.
Kein Spam, nie. Jederzeit abbestellbar.
Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack of commercial interest and safety-related concerns limit its clinical development. This cross-sectional study investigates the current landscape of clinical trials involving ibogaine, a non-classical psychedelic, focusing on its safety and efficacy. We extracted data from ClinicalTrials.Gov, EU Clinical Trials (https://euclinicaltrials.eu/), the EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/), and the International Clinical Trials Registry Platform (World Health Organization). After rigorous screening and deduplication, we analyzed nine trials. Our findings revealed considerable variability in methodologies, including fixed-dose and ascending-dose designs, diverse inclusion and exclusion criteria, and differing primary and secondary outcomes. Early-phase trials dominate, primarily focusing on pharmacokinetics, withdrawal symptom reduction, and safety monitoring. Key findings indicate significant differences in how safety concerns are addressed, particularly regarding ibogaine's cardiovascular risk. While preliminary evidence suggests potential therapeutic benefits, the absence of large-scale, late-phase trials limits definitive conclusions. Our study underscores the need for a standardized clinical framework to ensure reliable assessments of ibogaine's efficacy and safety. Lessons from research on classical psychedelics, and MDMA could help improve trial design and reduce issues related to blinding and expectancy bias.